UBS Group’s PTC Therapeutics PTCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q1
– Sell
-296,100
Closed -$9.6M – 8049
2015
Q4
$9.6M Buy
+296,100
New +$8.71M 0.01% 1435

Other funds holding PTCT

UBS Group's PTCT Position: Q3 2026 in Review

UBS Group increased its PTC Therapeutics (PTCT) stake by 617% in Q3 2026, buying an estimated $118M and bringing the position to 1,880,447 shares worth $122M. The position accounts for 0.02% of the portfolio, ranked #970.

UBS Group first reported a position in PTCT in Q4 2014 and has held it in 48 quarters since. 361 funds tracked by Wall St. Rank hold PTCT as of Q3 2026.

  • UBS Group held 1,880,447 shares of PTC Therapeutics worth $122M as of Q3 2026.
  • UBS Group bought 1,618,021 PTC Therapeutics shares in Q3 2026, an estimated $118M.
  • PTC Therapeutics made up 0.02% of UBS Group's portfolio in Q3 2026, its #970 holding.
  • UBS Group first reported a position in PTC Therapeutics in Q4 2014 and has held it in 48 quarters since.
  • 361 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.